BTIG analyst Lance Jessurun reaffirmed a Neutral rating on PayPal (NASDAQ:PYPL) stock, expressing caution ahead of the ...

In a report released today, Julian Harrison from BTIG maintained a Buy rating on Cullinan Management (CGEM – Research Report), with a price ...

BTIG Research began coverage on shares of Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) in a research report issued on Tuesday, MarketBeat reports. The brokerage set a “buy” rating and a ...

BTIG analyst Vincent Caintic maintained a Buy rating on Atlanticus Holdings (ATLC – Research Report) yesterday and set a price target of ...

Fintel reports that on January 28, 2025, BTIG initiated coverage of Arcturus Therapeutics Holdings (NasdaqGM:ARCT) with a Buy ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the ...

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, toda ...

But before that let's have a chartist view from BTIG's technical guru Jonathan Krinsky. He notes that the S&P 500's rally off this week's lows is quite impressive and sets up the stock barometer ...

Analysts at BTIG moved to the sidelines on online dating apps company Match Group (NASDAQ:MTCH) and lowered its investment rating to "Neutral" from "Buy" on Tuesday. The research firm said its ...

On Friday, BTIG initiated coverage on ImmunityBio Inc (NASDAQ:IBRX) with a Buy rating and a price target of $6.00. The firm sees potential in the company's lead product, ANKTIVA, an IL-15 receptor ...